Saxon Interests’s Moderna MRNA Stock Holding History

Saxon Interests’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$688K	Sell	9,831 -1,826	-16%	-$94.5K	0.19%	122
2026 Q1	$592K	Buy	11,657 +5	+0%	+$233	0.2%	127
2025 Q4	$344K	Buy	+11,652	New	+$317K	0.12%	154

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Saxon Interests's MRNA Position: Q2 2026 in Review

Saxon Interests reduced its Moderna (MRNA) stake by 16% in Q2 2026, selling an estimated $94.5K and leaving 9,831 shares worth $688K. The position accounts for 0.19% of the portfolio, ranked #122.

Saxon Interests first reported a position in MRNA in Q4 2025 and has held it in 3 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Saxon Interests held 9,831 shares of Moderna worth $688K as of Q2 2026.
Saxon Interests sold 1,826 Moderna shares in Q2 2026, an estimated $94.5K.
Moderna made up 0.19% of Saxon Interests's portfolio in Q2 2026, its #122 holding.
Saxon Interests first reported a position in Moderna in Q4 2025 and has held it in 3 quarters since.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Saxon Interests's 13F filing for Q2 2026, filed 12 Aug 2026.